This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Amgen oppose Regeneron in privilege dispute in US antitrust case over cholesterol drug

( September 13, 2024, 23:31 GMT | Official Statement) -- MLex Summary: Amgen wrote to a US magistrate judge to oppose Regeneron Pharmaceuticals’ letter regarding a privilege dispute in a case accusing Amgen of engaging in an anticompetitive drug bundling scheme over cholesterol reduction drugs. “Regeneron’s letter is full of rhetoric and unwarranted accusations, but is utterly lacking in support. Regeneron misrepresents the meaning of the privileged comment in dispute, omits crucial context that allows the comment to be understood, and inaccurately claims – without any evidence – that the comment was shared outside Amgen. Regeneron also fails to inform the court that it misrepresented the source of the privileged comment,” it wrote. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections